TREM2 blockade as an adjuvant for checkpoint inhibitors

Tech ID: T-019371

Disease indication – In combination with anti-PD-1 therapy for cancer. Anti-PD-1 therapy is currently approved for:

  • Melanoma
  • Non-small cell lung cancer
  • Hodgkin’s lymphoma
  • Renal cell carcinoma
  • Head & neck squamous cell carcinoma
  • Squamous cell lung cancer
  • Cutaneous squamous cell carcinoma

Drug format – Monoclonal antibody

Drug class – First-in-class

Target – TREM2

Research stage and preliminary data – The inventors performed initial in vivo proof-of-concept experiments using an MCA-induced sarcoma model in wild type mice. While mice treated with anti-PD-1 therapy saw a marked reduction in tumor size, the addition of anti-TREM2 resulted in complete tumor regression in all mice studied.

Background – Checkpoint inhibitor therapies have proved successful in a broad variety of cancer types. However, the efficacy is limited by both normal and tumor-mediated mechanisms of immunosuppression. Checkpoint inhibitor efficacy can be restored by blocking that immunosuppression or by overwhelming the suppressive signals with stimulatory signals.

Mode of action – Blocking TREM2 curbs cancer growth and induces expansion of immunostimulatory myeloid cells in the tumor microenvironment. The resulting immune stimulation increases the efficacy of anti-PD-1 immunotherapy.

Competitive edge – Currently, the only TREM2 antibody in clinical trials is a TREM2 agonist being studied in Alzheimer’s disease (AL002 from Alector).


Patent status – Pending

Web Links – Colonna Profile & Lab




Poranki, Deepika

Create a Collection